secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2026-08-13T11:32:23+00:00
Accession:  0001410098-26-000054
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q2 revenue $101.9M, net income $26.0M; raises FY26 adjusted EBITDA guidance
--------------------------------------------------------------------------------

- Q2 2026 consolidated revenue of $101.9M; net income of $26.0M; adjusted EBITDA of $58.7M; diluted EPS $0.29.
- DefenCath net revenue $66.1M; acquired Melinta portfolio contributed $35.8M.
- FY26 revenue guidance maintained at $325-345M; adjusted EBITDA guidance raised to $125-140M.
- New multi-year DefenCath supply agreement with an LDO; now covers all top 5 U.S. dialysis providers.
- REZZAYO sNDA for prophylaxis of invasive fungal disease expected Q3 2026; FDA action anticipated H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/0001410098-26-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/crmd-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001410098-26-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer